STC-004 was well-tolerated at all doses tested, SiteOne previously reported. Eli Lilly stated STC-004 is "Phase II ready" and “may represent a next-generation, non-opioid treatment for patients ...

Called STC-004, the treatment is a a Nav1.8 inhibitor that is ready for Phase 2 testing. Lilly said STC-004 might represent a next-generation, non-opioid treatment for chronic pain.

The transaction includes STC-004, a Phase 2 ready Nav1.8 inhibitor being studied for the treatment of pain. STC-004 may represent a next-generation, non-opioid treatment for patients suffering ...

SiteOne’s STC-004 is an oral small molecule designed to target NaV1.8. In February, SiteOne reported Phase 1 results showing STC-004 was rapidly absorbed with a half-life that supports once ...

Eli Lilly's acquisition of SiteOne Therapeutics and STC-004 brings a once-daily NaV1.8 candidate, with early promising results but limited clinical data so far.

Like Vertex's Journavx (suzetrigine), cleared by the FDA in February for moderate-to-severe acute pain, STC-004 is an oral inhibitor of the NaV1.8 sodium channel, blocking a pain-signalling ...

Upon the completion of the deal, the company expects to continue the development of STC-004 along with the SiteOne team, paving way for advancement of new non-opioid medicines for pain management.

Perhaps STC-004 will flop in upcoming clinical trials. But there's something important to highlight about Eli Lilly that this acquisition brings to light. Beyond the weight management market.

STC-004 may represent a next-generation, non-opioid treatment for patients suffering from chronic pain. "The global burden of chronic pain continues to increase, ...